Compare Crispr Therapeutics AG (CRSP) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Visa Inc — how do they compare? Crispr Therapeutics AG trades at $51.6 (market cap $4.97B), while Visa Inc trades at $355.21 (market cap $677.06B). The key difference: Visa Inc is far larger — about 136.2× Crispr Therapeutics AG's market cap, and Visa Inc pays a 0.75% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | V | |
|---|---|---|
Market Cap | $4.97B | $677.06B |
Sector | Health | Financials |
52-Week High | $76.78 | $362.13 |
52-Week Low | $44.34 | $295.52 |
Enterprise Value | $3.32B | $687.65B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Visa (V) trades at $356.02, down 0.48% on the day, with strong technical momentum showing bullish moving averages and support at $354. The company maintains exceptional profitability with 51.68% net income margins and has beaten earnings estimates for three consecutive quarters. Recent developments include AI-driven commerce initiatives and stablecoin partnerships positioning Visa at the forefront of payment innovation.
With 85% analyst buy ratings and a $394.50 consensus price target suggesting 11% upside, Visa offers growth potential despite premium valuations. Key risks include fintech competition and regulatory pressures, but strong cash flow generation and consistent execution support the bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
